A protective effect of the TORC1 antagonist rapamycin has been demonstrated in models for Parkinson’s disease 57, Huntington’s disease 56, spinoceribellar ataxia type 3 58 and retinal degeneration mediated by mitochondrial dysfunction 59. This evidence concerns the gene CRTC1 and Parkinson disease.